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Background: Children with severe atopic dermatitis (AD) have limited treatment options.
Objective: We report the efficacy and safety of dupilumab 1 topical corticosteroids (TCS) in children aged
6-11 years with severe AD inadequately controlled with topical therapies.
Methods: In this double-blind, 16-week, phase 3 trial (NCT03345914), 367 patients were randomized 1:1:1
to 300 mg dupilumab every 4 weeks (300 mg q4w), a weight-based regimen of dupilumab every 2 weeks
(100 mg q2w, baseline weight\30 kg; 200 mg q2w, baseline weight$30 kg), or placebo; with concomitant
medium-potency TCS.
Results: Both the q4w and q2w dupilumab 1 TCS regimens resulted in clinically meaningful and
statistically significant improvement in signs, symptoms, and quality of life (QOL) versus placebo 1 TCS in
all prespecified endpoints. For q4w, q2w, and placebo, 32.8%, 29.5%, and 11.4% of patients, respectively,
achieved Investigator’s Global Assessment scores of 0 or 1; 69.7%, 67.2%, and 26.8% achieved $75%
improvement in Eczema Area and Severity Index scores; and 50.8%, 58.3%, and 12.3% achieved $4-point
reduction in worst itch score. Response to therapy was weight-dependent: optimal dupilumab doses for
efficacy and safety were 300 mg q4w in children \30 kg and 200 mg q2w in children $30 kg.
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Conjunctivitis and injection-site reactions were more common with dupilumab 1 TCS than with
placebo 1 TCS.
Limitations: Short-term 16-week treatment period; severe AD only.
Conclusion: Dupilumab 1 TCS is efficacious and well tolerated in children with severe AD, significantly
improving signs, symptoms, and QOL. ( J Am Acad Dermatol 2020;83:1282-93.)
Key words: atopic dermatitis; children; dupilumab; pediatric; severe.
Atopic dermatitis (AD) is
one of the most common
skin disorders in children
and the leading contributor
to the global burden of skin
disease.1,2 In children with
moderate-to-severe AD, skin
lesions often involve a large
body surface area (BSA), and
the related pruritus, sleep
deprivation, activity restric-
tion, poor school perfor-
mance, depression, and
anxiety have a greater impact
on quality-of-life (QOL) for
patients and their caregivers
than other common skin
disorders such as psoriasis
and urticaria.3-5
AD begins before the age
of 5 years inmore than 85%of
patients and persists into
adulthood in half the cases.6,7
Despite the chronic nature of
AD, treatment in children is
often limited to short-term
topical corticosteroids (TCS),
with topical calcineurin inhib-
itors as second-line therapy.8,9
Guidelines discourage sys-
temic corticosteroids owing
to the risk of rebound
after short-term treatment,
unfavorable benefit-to-risk
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CAPSULE SUMMARY
d Children with severe atopic dermatitis
inadequately controlled with topical
therapies have limited treatment
options.
d Dupilumab biologic therapy targeting
the shared receptor component for
interleukin-4 and interleukin-13
improves outcomes in children with
severe atopic dermatitis inadequately
controlled with topical corticosteroids,
including signs, symptoms, and quality-
of-life, with an acceptable safety profile.
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ratio, and multiple adverse events (AEs) associated
with their use.10,11 Although other systemic agents
have been used off-label, the risk of serious AEs
associated with these agents and the lack of high-
level evidence for long-term efficacy makes them
especially inappropriate for this age group.12
Consequently, systemic treatments are offered only
as a last resort for themost intractable cases,8 resulting
in a large unmet need for children whose disease is
inadequately controlled with topical therapy.
Dupilumab is a fully human, VelocImmune-
derived monoclonal antibody13,14 that blocks the
shared receptor component for interleukin-4 and
interleukin-13. Dupilumab clinical trials have shown
that these cytokines are key and central drivers of
multiple type 2 inflammatory diseases. Dupilumab
use is approved in the United States and European
Union and other countries for adults and adolescents
with moderate-to-severe AD, moderate-to-severe
asthma with evidence of type 2 inflammation or
eosinophilia, and adults with chronic rhinosinusitis
and nasal polyps. Dupilumab significantly improves
signs, symptoms, and QOL in adults and adolescents
with moderate-to-severe AD, with an acceptable
safety profile.15-19 We now report results from a
phase 3 trial of dupilumab with concomitant TCS in
children age 6-11 years with severe AD inadequately
controlled with topical therapies.
METHODS
Study design
LIBERTY AD PEDS was a randomized, double-
blind, placebo-controlled, phase 3 trial, registered at
Clinicaltrials.Gov (identifier NCT03345914) on
November 14, 2017, and conducted at 61 sites in
Canada, Czech Republic, Germany, Poland, United
Kingdom, and United States. The study was con-
ducted in accordance with the provisions of the
Declaration of Helsinki, the International
Conference on Harmonization Good Clinical
Practice guideline, and applicable regulatory re-
quirements. The protocol was reviewed and
approved by institutional review boards or ethics
committees at all study sites. Assent was obtained
from each patient, and written informed assent was
obtained from their parents or legal guardians before
study participation. Patients were enrolled from
November 17, 2017, to February 28, 2019. The study
concluded on September 9, 2019.
The study design included screening up to
9 weeks, TCS standardization for 2 weeks, treatment
for 16 weeks, and follow-up for 12 weeks (only for
those patients who declined or were ineligible to
participate in a subsequent open-label extension
study, NCT02612454).
Patients and treatment
Key inclusion criteria were children age 6-11 years
with AD (American Academy of Dermatology
consensus criteria20) diagnosed $1 year before
screening; Investigator’s Global Assessment (IGA)
score of 4, Eczema Area and Severity Index (EASI)
score $21, affected BSA $15%, weekly averaged
baseline worst itch score (Peak Pruritus Numerical
Rating Scale [NRS]) $4; weight $15 kg; and docu-
mented history of inadequate response to topical AD
medication within 6 months of baseline.
Patients were randomized 1:1:1 to dupilumab
1 TCS every 2 weeks (q2w 1 TCS; weight-tiered:
baseline weight 15 to\30 kg, 100 mg q2w 1 TCS,
200 mg loading dose; baseline weight $30 kg,
200 mg q2w 1 TCS, 400 mg loading dose);
dupilumab 1 TCS every 4 weeks (300 mg
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BSA: body surface area
CDLQI: Children’s Dermatology Life Quality
Index
DFI: Dermatitis Family Impact
EASI: Eczema Area and Severity Index
EASI-50: $50% improvement in EASI
EASI-75: $75% improvement in EASI
EASI-90: $90% improvement in EASI
FAS: full analysis set
IGA: Investigator’s Global Assessment
NRS: Numerical Rating Scale
POEM: Patient-Oriented Eczema Measure
QOL: quality of life
TCS: topical corticosteroids
TEAE: treatment-emergent adverse event
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q4w 1 TCS; 600 mg loading dose regardless of
weight); or matching placebo 1 TCS.
All patients received concomitant once-daily
medium-potency TCS starting 2 weeks before base-
line. Rescue treatment with high-potency TCS or
systemic therapy was permitted for patients with an
IGA score of 4 or intolerable symptoms during the
treatment period. Very-high-potency TCS were pro-
hibited, even as rescue.
Randomization was performed using a central-
ized scheme, provided by an interactive response
system assigned to the designated study pharmacist
or qualified designee, and stratified by baseline
weight (\30 kg vs $30 kg) and region (North
America vs Europe). Patients and all other personnel
were blinded to all randomization procedures.
Outcomes
The primary endpoint was the proportion of
patients with an IGA score of 0 or 1 (clear or almost
clear) at week 16; the co-primary endpoint in the
European Union and EU reference countries was
$75% improvement in EASI (EASI-75) from baseline
to week 16. Key secondary endpoints included
percent change in EASI and weekly average of
Peak Pruritus NRS from baseline to week 16.
Statistical analysis
A sample size of 240 patients was calculated to
have sufficient power to discriminate between
placebo 1 TCS and the dupilumab 1 TCS groups
at a 2-sided, 0.05 significance level. Because of an
operational error, 68 patients were potentially un-
blinded, and the sample size was increased to
maintain study balance and power.
The primary analysis was performed on the full
analysis set (FAS), which included all randomized
patients. A modified FAS, defined as all randomized
patients but excluding the 68 potentially unblinded
patients, was added as a sensitivity analysis for the
co-primary and selected secondary endpoints.
Efficacy was assessed in the FAS. The primary
analysis for all efficacy variables compared the 2
dupilumab treatment groups (100/200 mg
q2w 1 TCS and 300 mg q4w 1 TCS) with the
placebo 1 TCS group. The co-primary endpoints
and categorical secondary endpoints were assessed
using a CochraneManteleHaenszel test adjusted by
randomization strata (baseline weight group and
region), with patients who received rescue medica-
tion or with missing values considered nonre-
sponders. Continuous secondary endpoints were
analyzed using multiple imputation with analysis of
covariance. Efficacy data after rescue medication use
were treated as missing and imputed using multiple
imputation. Time-to-event endpoints were analyzed
using the Cox proportional hazard model.
A hierarchical procedure was used to control the
overall type-1 error rate at 0.05 for the primary
endpoint and secondary endpoints across the 2
dupilumab 1 TCS dose regimens versus placebo.
Safety was assessed in all treated patients who
received $1 dose of study drug (safety analysis set).
All analyses were performed using SAS version 9.4.
RESULTS
Patients
Of 474 patients screened, 367 patients were
enrolled, randomized, and included in the FAS, of
whom 362 (98.6%) received $1 dose of study
treatment and were included in the safety analysis
set. Among the 5 patients (1.4%) randomized and not
treated, 3 patients were randomized in error and 2
patients withdrew consent. As a result, 351 patients
(95.6%) completed the study treatment.
Baseline demographics and disease characteris-
tics were balanced among treatment groups and
were consistent with severe disease (Table I).
Patients had high rates of atopic comorbidities,
including asthma, allergic rhinitis, and food allergies;
91.7% (332/362) had $1 atopic comorbidity. One
third of patients had received prior systemic treat-
ment for AD. At baseline, Children’s Dermatology
Life Quality Index (CDLQI) and Dermatitis Family
Impact (DFI) scores showed a significant impact of
AD on children and their families.
Efficacy
Both of the dupilumab 1 TCS regimens (weight-
tiered 100/200 mg q2w 1 TCS and noneweight-
tiered 300 mg q4w 1 TCS) versus placebo 1 TCS
significantly improved all prespecified efficacy end-
points (Table II). At week 16, significantly more
patients receiving dupilumab q2w 1 TCS and
q4w 1 TCS versus placebo 1 TCS achieved the
primary endpoint of an IGA score of 0 or 1
(q2w 1 TCS, 29.5% [P = .0004]; q4w 1 TCS, 32.8%
[P\ .0001]; placebo 1 TCS, 11.4%; Fig 1).
Significantly more patients receiving dupilumab
1 TCS achieved EASI-75 at week 16 than those
receiving placebo 1 TCS (q2w 1 TCS, 67.2%;
q4w 1 TCS, 69.7%; placebo 1 TCS, 26.8%;
P \ .0001). Both IGA scores of 0 or 1 and EASI-75
showed ongoing improvement at week 16 (Fig 1),
suggesting that the maximal effect had not yet been
achieved. Both of the dupilumab 1 TCS regimens
showed significantly better efficacy than
placebo 1 TCS in additional disease severity mea-
sures, including $50% or $90% improvement from
baseline in EASI scores (EASI-50 or EASI-90), BSA,
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Table I. Baseline demographics and clinical characteristics
Demographics and
characteristics

































Age, mean (SD), years 8.3 (1.8) 8.5 (1.7) 8.5 (1.7) 7.1 (1.3) 7.5 (1.4) 7.6 (1.4) 9.5 (1.3) 9.5 (1.5) 9.5 (1.4)
Race, n (%)
White 77 (62.6) 89 (73.0) 88 (72.1) 40 (65.6) 45 (73.8) 43 (68.3) 37 (59.7) 44 (72.1) 45 (76.3)
Black/African American 23 (18.7) 19 (15.6) 20 (16.4) 9 (14.8) 9 (14.8) 12 (19.0) 14 (22.6) 10 (16.4) 8 (13.6)
Asian 13 (10.6) 5 (4.1) 10 (8.2) 7 (11.5) 4 (6.6) 6 (9.5) 6 (9.7) 1 (1.6) 4 (6.8)
Other 9 (7.3) 8 (6.6) 2 (1.6) 4 (6.6) 3 (4.9) 1 (1.6) 5 (8.1) 5 (8.2) 1 (1.7)
Not reported/missing 1 (0.8) 1 (0.8) 2 (1.6) 1 (1.6) 0 1 (1.6) 0 1 (1.6) 1 (1.7)
Sex, male, n (%) 61 (49.6) 57 (46.7) 65 (53.3) 30 (49.2) 27 (44.3) 32 (50.8) 31 (50.0) 30 (49.2) 33 (55.9)
Weight, kg, mean (SD) 31.5 (10.8) 31.0 (9.4) 32.1 (10.8) 23.3 (3.4) 23.8 (3.0) 24.5 (3.5) 39.5 (9.5) 38.1 (8.0) 40.2 (10.0)
Weight group, n (%)
\30 kg 61 (49.6) 61 (50.0) 63 (51.6) 61 (100) 61 (100) 63 (100) 0 0 0
$30 kg 62 (50.4) 61 (50.0) 59 (48.4) 0 0 0 62 (100) 61 (100) 59 (100)
BMI, kg/m2, mean (SD) 17.9 (3.9) 17.6 (2.9) 18.0 (3.7) 16.0 (2.5) 15.7 (1.3) 16.1 (1.7) 19.8 (4.1) 19.5 (2.9) 20.2 (4.0)
Duration of AD, years, mean (SD) 7.2 (2.2) 7.4 (2.4) 7.2 (2.3) 6.3 (1.7) 6.8 (1.7) 6.4 (2.1) 8.0 (2.2) 8.0 (2.9) 8.1 (2.3)
EASI score, mean (SD) 39.0 (12.0) 37.4 (12.5) 37.3 (10.9) 38.9 (12.6) 36.9 (12.4) 37.5 (10.0) 39.0 (11.5) 37.8 (12.6) 37.1 (11.8)
Weekly average of daily NRS, mean (SD) 7.7 (1.5) 7.8 (1.6) 7.8 (1.5) 7.6 (1.6) 7.9 (1.5) 7.9 (1.5) 7.8 (1.5) 7.7 (1.7) 7.6 (1.5)
Percent BSA affected, mean (SD) 60.2 (21.5) 54.8 (21.6) 57.8 (20.0) 62.0 (20.9) 54.6 (21.9) 61.5 (19.4) 58.4 (22.1) 54.9 (21.4) 53.9 (20.2)
SCORAD, mean (SD) 72.9 (12.0) 75.6 (11.7) 72.3 (10.8) 73.0 (12.6) 75.5 (12.6) 73.3 (10.4) 72.8 (11.5) 75.8 (10.9) 71.2 (11.3)
CDLQI, mean (SD) 14.6 (7.4) 16.2 (7.9) 14.5 (6.8) 16.1 (6.9) 16.9 (8.1) 16.0 (7.0) 13.2 (7.7) 15.5 (7.7) 13.0 (6.3)
POEM, mean (SD) 20.7 (5.5) 21.3 (5.5) 20.5 (5.5) 21.1 (4.9) 21.5 (6.0) 21.1 (5.6) 20.4 (6.0) 21.1 (5.1) 19.9 (5.3)
DFI, mean (SD) 15.0 (7.5) 16.9 (8.7) 14.9 (7.1) 16.1 (7.6) 17.7 (8.9) 16.2 (6.8) 14.0 (7.4) 16.1 (8.4) 13.5 (7.1)
PROMIS anxiety, mean (SD) 57.3 (11.6) 59.8 (13.7) 58.6 (11.3) 58.9 (11.8) 60.3 (13.6) 60.6 (10.5) 55.8 (11.4) 59.3 (13.8) 56.5 (11.8)
PROMIS depression, mean (SD) 55.0 (12.1) 58.1 (12.8) 56.3 (11.2) 54.4 (12.3) 58.8 (13.1) 57.8 (10.6) 55.6 (11.9) 57.4 (12.5) 54.7 (11.7)
History of atopic morbidities not
including AD, n/N1 (%)
111/120 (92.5) 107/120 (89.2) 114/122 (93.4) NA
Food allergy 83/120 (69.2) 75/120 (62.5) 75/122 (61.5) NA
Other allergies 81/120 (67.5) 67/120 (55.8) 79/122 (64.8) NA
Allergic rhinitis 72/120 (60.0) 73/120 (60.8) 73/122 (59.8) NA
Asthma 54/120 (45.0) 55/120 (45.8) 60/122 (49.2) NA
Allergic conjunctivitis
(keratoconjunctivitis)
16/120 (13.3) 14/120 (11.7) 14/122 (11.5) NA
Hives 8/120 (6.7) 14/120 (11.7) 14/122 (11.5) NA
Chronic rhinosinusitis 4/120 (3.3) 5/120 (4.2) 2/122 (1.6) NA
Eosinophilic esophagitis 0 1/120 (0.8) 1/122 (0.8) NA
Nasal polyps 0 0 2/122 (1.6) NA
History of systemic medication for AD, n/N1
(%)
36/120 (30.0) 42/120 (35.0) 40/122 (32.8) NA
Patients receiving prior corticosteroids 17/120 (14.2) 25/120 (20.8) 30/122 (24.6) NA
Patients receiving prior systemic
nonsteroidal immunosuppressants
22/120 (18.3) 23/120 (19.2) 16/122 (13.1) NA
Azathioprine 0 2/120 (1.7) 2/122 (1.6) NA
Cyclosporine 12/120 (10.0) 17/120 (14.2) 11/122 (9.0) NA
Methotrexate 11/120 (9.2) 7/120 (5.8) 3/122 (2.5) NA
Mycophenolate 2/120 (1.7) 2/120 (1.7) 1/122 (0.8) NA
Eosinophils, median (Q1eQ3), 3109/L 0.7 (0.4e1.1) 0.8 (0.4e1.1) 0.6 (0.4e1.2) NA
AD, Atopic dermatitis; BMI, body mass index; BSA, body surface area; CDLQI, Children’s Dermatology Life Quality Index; DFI, Dermatitis Family Impact; EASI, Eczema Area and Severity Index; N1,
number of patients in the safety analysis set; NA, not available; NRS, Numerical Rating Scale; POEM, Patient-Oriented Eczema Measure; PROMIS, Patient-Reported Outcomes Measurements






































Table II. Efficacy outcomes
Endpoints
































Proportion of patients with IGA 0 or 1,
n (%)
14 (11.4) 40 (32.8)*,7 36 (29.5)y,1 8 (13.1) 18 (29.5)z,x 13 (20.6) 6 (9.7) 22 (36.1)y,x 23 (39.0)y,z
Proportion of patients with EASI-75, n (%) 33 (26.8) 85 (69.7)*,8 82 (67.2)*,2 17 (27.9) 46 (75.4)*,z 38 (60.3)y,z 16 (25.8) 39 (63.9)*,z 44 (74.6) *,z
Secondary endpoints in the statistical
testing hierarchy
% change in EASI, LS mean (SE) 48.6 (2.5) 82.1 (2.4)*,9 78.4 (2.4)*,3 e49.1 (3.3) e84.3 (3.0)*,z e76.7 (3.0)*,z e48.3 (3.6) e79.9 (3.6)*,z e80.4 (3.6)*,z
Proportion of patients with EASI-50, n (%) 53 (43.1) 111 (91.0)*,10 101 (82.8)*,4 26 (42.6) 58 (95.1)*,z 50 (79.4)*,z 27 (43.5) 53 (86.9)*,z 51 (86.4)*,z
% change in weekly average of daily Peak
Pruritus NRS, LS mean (SE)
25.9 (2.9) 54.6 (2.9)*,11 57.0 (2.8)*,5 e27.0 (4.2) e55.1 (3.9)*,z e56.1 (3.9)*,z e25.0 (4.0) e54.3 (4.2)*,z e58.2 (4.0)*,z
Proportion of patients with $4-point
reduction in weekly average of daily
Peak Pruritus NRS, n/N1 (%)
15/122 (12.3) 61/120 (50.8)*,12 70/120 (58.3)*,6 7/60 (11.7) 33/61 (54.1)*,z 35/63 (55.6)*,z 8/62 (12.9) 28/59 (47.5)*,z 35/57 (61.4)*,z
Proportion of patients with $3-point
reduction in weekly average of daily
Peak Pruritus NRS, n/N2 (%)
26/123 (21.1) 73/121 (60.3)*,15 81/120 (67.5)*,13 11/61 (18.0) 38/61 (62.3)*,z 43/63 (68.3)*,z 15/62 (24.2) 35/60 (58.3)y,z 38/57 (66.7)*,z
Proportion of patients with EASI-90, n (%) 9 (7.3) 51 (41.8)*,16 37 (30.3)*,14 4 (6.6) 28 (45.9)*,z 16 (25.4)z,jj 5 (8.1) 23 (37.7)*,z 21 (35.6)y,z
Change in POEM, LS mean (SE) 5.3 (0.7) 13.6 (0.7)*,20 13.4 (0.7)*,17 e5.9 (1.0) e14.0 (1.0)*,z e13.3 (0.9)*,z e4.7 (0.9) e13.2 (0.9)*,z e13.6 (0.9)*,z
Change in CDLQI, LS mean (SE) 6.4 (0.5) 10.6 (0.5)*,21 10.7 (0.5)*,18 e7.2 (0.8) e11.5 (0.7)*,z e11.6 (0.7)*,z e5.6 (0.7) e9.7 (0.6)*,z e9.8 (0.6)*,z
% change in SCORAD, LS mean (SE) 29.8 (2.3) 62.4 (2.1)*,22 60.2 (2.1)*,19 e28.9 (3.1) e65.3 (2.9)*,z e58.1 (2.8)*,z e30.7 (3.3) e59.3 (3.1)*,z e62.7 (3.1)*,z
Other secondary endpoints
Change in weekly average of daily Peak
Pruritus NRS, LS mean (SE)
2.1 (0.2) 4.2 (0.2)*,z 4.5 (0.2)*,z NA
Change in percent BSA affected, LS mean
(SE)
21.7 (1.7) 40.5 (1.6)*,z 39.4 (1.6)*,z e23.9 (2.3) e43.2 (2.2)*,z e40.6 (2.1)*,z e19.8 (2.5) e38.2 (2.5)*,z e38.4 (2.5)*,z
Change in DFI, LS mean (SE) 6.8 (0.5) 10.8 (0.5)*,z 10.9 (0.5)*,z NA
Change in PROMIS anxiety, LS mean (SE) 10.2 (0.9) 13.2 (0.9)z,x 13.5 (0.9)z,jj NA
Change in PROMIS depression, LS mean
(SE)
7.4 (0.8) 12.8 (0.8)*,z 11.9 (0.8)*,z NA
Mean proportion of TCS-free days (SD) 0.1 (0.2) 0.2 (0.2)z,jj 0.2 (0.2)z,jj NA
Mean weekly use of low- or medium-
potency TCS, LS mean (SE), g
20.1 (1.4) 15.0 (1.4)z,jj 14.4 (1.4)z,jj NA
Change in SCORAD sleep component
VAS, LS mean (SE){
2.0 (0.3) 4.3 (0.2)*,z 4.5 (0.2)*,z 2.0 (0.4) 4.6 (0.3)*,z 4.5 (0.3)*,z 2.1 (0.4) 3.9 (0.3)y,z 4.5 (0.3)*,z
Change in POEM sleep item, LS mean (SE)# 1.0 (0.1) 2.1 (0.1)*,z 2.1 (0.1)*,z 1.0 (0.2) 2.2 (0.2)*,z 1.9 (0.2)y,z 0.9 (0.2) 2.0 (0.2)*,z 2.3 (0.2)*,z
Change in CDLQI sleep item, LSmean (SE)** 0.6 (0.1) 1.4 (0.1)*,z 1.4 (0.1)*,z 0.7 (0.1) 1.5 (0.1)*,z 1.4 (0.1)*,z 0.6 (0.1) 1.2 (0.1)*,z 1.3 (0.1)*,z
Superscript numbers (1-22) show the order in the statistical testing hierarchy; all P-values in the hierarchy were controlled for multiplicity.
BSA, Body surface area; CDLQI, Children’s Dermatology Life Quality Index; DFI, Dermatitis Family Index (10-item questionnaire assessing the impact of having a child with atopic dermatitis on family
quality of life); EASI, Eczema Area and Severity Index; EASI-50/-75/-90,$50%/75%/90% improvement from baseline in EASI scores; IGA, Investigator’s Global Assessment; LS, least-squares; N1, number
of patients with baseline NRS score$4 and nonmissing values at each visit; N2, number of patients with baseline NRS score$3 and nonmissing values at each visit; NA, not available; NRS, Numerical
Rating Scale; POEM, Patient-Oriented Eczema Measure; PROMIS, Patient-Reported Outcomes Measurements Information Systems; q2w, every 2 weeks; q4w, every 4 weeks; SCORAD, SCORing Atopic
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and SCORing Atopic Dermatitis (SCORAD; P\.0001,
all comparisons). The least-squares mean (6standard
error) percent change in EASI from baseline to week
16 was significantly greater among patients treated
with dupilumab 1 TCS, with reductions of
78.4 6 2.4% for q2w 1 TCS and 82.1 6 2.4% for
q4w 1 TCS versus 48.6 6 2.5% for placebo 1 TCS
(Table II; Fig 1).
At week 16, significantly more patients receiving
dupilumab 1 TCS than placebo 1 TCS showed $3-
and $4-point improvement in weekly average of
Peak Pruritus NRS (P\.0001, all comparisons; Fig 2),
with consistently higher proportions in the
dupilumab1 TCS groups achieving$4-point reduc-
tion as early as week 4 (q2w 1 TCS, P = .0044;
q4w 1 TCS, P\ .0001).
Dupilumab 1 TCS significantly reduced patient-
reported symptoms of AD, effects on QOL, and
symptoms of anxiety and depression, as assessed
by mean change from baseline in Patient-Oriented
Eczema Measure (POEM), CDLQI, DFI, and Patient-
Reported Outcomes Measurements Information
Systems anxiety and depression scores21 (Table II).
Dupilumab 1 TCS also improved sleeplessness as
assessed with the SCORAD sleep component, the
POEM sleep item, and the CDLQI sleep item
(Table II).
The placebo 1 TCS regimen had a higher pro-
portion of patients requiring rescue medication
(19.2%) than either dupilumab regimen (q2w 1
TCS, 4.9%; q4w 1 TCS, 2.5%). Sensitivity analyses
(all observed values regardless of rescue treatment
use) were consistent with the primary analyses.
Analyses in the modified FAS were consistent with
the FAS, indicating no introduction of bias due to the
potential unblinding.
Efficacy and pharmacokinetic analyses by
weight strata
Prespecified analyses by weight strata indicated
differences between treatment groups on key effi-
cacy parameters (Table II; Fig 1). In the \30-kg
stratum, a numerically greater proportion of patients
receiving dupilumab 300mg q4w1 TCS achieved an
IGA score of 0 or 1 and EASI-50/75/90 versus 100 mg
q2w 1 TCS; notably, mean percent change EASI
improvement was greater for 300 mg q4w 1 TCS
than for 100 mg q2w1 TCS in the\30-kg stratum at
all time points (Fig 1). In the $30-kg stratum, a
numerically greater proportion of patients random-
ized to dupilumab 200 mg q2w 1 TCS than 300 mg
q4w1 TCS achieved an IGA score of 0 or 1, EASI-75,
and$4- and$3-point reductions in worst itch score.
Consistent with the efficacy analyses, the dupilu-
mab 300 mg q4w 1 TCS regimen maintained
substantially higher trough blood levels than did the
100 mg q2w 1 TCS regimen in the\30-kg stratum
(week 16meanCtrough 98.7mg/L vs 62.6mg/L). In the
$30-kg group, the dupilumab 200 mg q2w 1 TCS
regimenmaintained consistently higher trough blood
levels than did the 300 mg q4w 1 TCS regimen
(86.0 mg/L vs 53.9 mg/L). Exposureeresponse re-
lationships over time, assessed by quartile analyses of
exposure for percent change from baseline in EASI
and percentage of patients achieving an IGA score of
0 or 1 and logistic regression for binary endpoints
(EASI-50, EASI-75, EASI-90, and IGA 0 or 1), indicated
a trend for increasing drug effect with increasing
Ctrough (data not shown).
Safety
Overall incidence of treatment-emergent AEs
(TEAEs) was lower in the dupilumab 1 TCS groups
(Table III). Two patients receiving placebo 1 TCS
and two receiving dupilumab 300 mg q4w 1 TCS
reported serious TEAEsdnone related to the study
drug. Treatment discontinuations due to AEs were
uncommon (placebo 1 TCS, n = 2; dupilumab 100/
200 mg q2w 1 TCS, n = 2). No deaths or treatment-
related events of hypersensitivity or anaphylaxis
occurred during the study. As in previous dupilumab
trials, injection-site reactions were more common
with dupilumab (none were severe or led to discon-
tinuation), as was conjunctivitis; all but 1 conjuncti-
vitis event were of mild-to-moderate severity. One
patient receiving dupilumab 200 mg q2w 1 TCS
discontinued treatment because of bacterial conjunc-
tivitis of moderate severity. Most patients with
conjunctivitis recovered or were recovering with
standard ophthalmic treatments during study drug
treatment. The highest incidence of conjunctivitis
(20.6%) occurred in the treatment group with the
lowest exposure (100 mg q2w 1 TCS).
Consistent with long-term experience with dupi-
lumab,22 infection (including skin infections and
herpes viral infections) was lower with
dupilumab 1 TCS than with placebo 1 TCS. In this
patient population with a high burden of comorbid
type 2 inflammatory diseases, and as would be
expected given the demonstrated efficacy of dupi-
lumab for these conditions, incidence of type 2
inflammatory AEs was lower with higher dupilumab
exposure. Among patients\30 kg, there was a trend
toward a lower incidence of AEs of AD exacerbation,
asthma, and allergic rhinitis in the dupilumab 300
mg q4w1 TCS group than in the 100 mg q2w1 TCS
group (Table III). A similar trend was noted in
patients $30 kg, with a lower incidence for 200 mg
q2w 1 TCS than for 300 mg q4w 1 TCS.
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Fig 1. Atopic dermatitis. Proportion of patients achieving co-primary endpoints of an IGA
score of 0 or 1 and EASI-75, and the LS mean percentage change in EASI over time in the overall
population and the baseline weight\30-kg and $30-kg subgroups. EASI, Eczema Area and
Severity Index; EASI-75, $75% improvement from baseline in EASI scores; IGA, Investigator’s
Global Assessment; LS, least-squares; q2w, every 2 weeks; q4w, every 4 weeks; TCS, topical
corticosteroids. *P\.05; **P\.001; ***P\.0001; all P values in the weight strata are nominal.
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DISCUSSION
In children age 6-11 years with severe AD
inadequately controlled with topical medications,
16 weeks of dupilumab1 TCS resulted in statistically
significant, clinically meaningful, and rapid improve-
ments in AD signs and symptoms, including itch,
anxiety, depression, sleep, and QOL. As most
efficacymeasures were continuing to show improve-
ment at week 16, it is possible that further benefit
would accrue with longer treatment. Overall, effi-
cacy of both dupilumab regimens (q2w 1 TCS and
q4w 1 TCS) in children with severe AD was similar
to that reported in adults15-17 and adolescents with
moderate-to-severe AD.18,19
In this phase 3 study, a monthly regimen of
dupilumab (300 mg q4w 1 TCS) was compared
with a weight-based dosing regimen (100 mg
q2w 1 TCS, patients \30 kg; 200 mg q2w 1 TCS,
patients $30 kg). In analyses by prespecified base-
line weight strata, optimal doses for efficacy and
safety were 300 mg q4w 1 TCS in\30-kg and 200
mg q2w 1 TCS in $30-kg children. These 2 dose
regimens have recently been approved by the US
Food and Drug Administration.23
Data were consistent with the known dupilumab
safety profile. As with previous studies of dupilumab
in AD, injection-site reactions and conjunctivitis
were the only 2 TEAEs for which incidence
notably increased for dupilumab 1 TCS versus
placebo 1 TCS; most cases were of mild-to-
moderate severity and resolved during the trial.














Proportion of patients with ≥3-point





















Placebo + TCS (n = 123)
Dupilumab 300 mg q4w + TCS (n = 121)
Dupilumab 100/200 mg q2w + TCS (n = 120)
Placebo + TCS (n = 122)
Dupilumab 300 mg q4w + TCS (n = 120)









































Proportion of patients with ≥3-point
improvement from baseline over time:
Baseline weight ≥ 30 kg
≥30 kg Placebo + TCS (n = 62)
≥30 kg Dupilumab 300 mg q4w + TCS (n = 60)
≥30 kg Dupilumab 200 mg q2w + TCS (n = 57)
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Week
Proportion of patients with ≥3-point
improvement from baseline over time:
Baseline weight < 30 kg
<30 kg Placebo + TCS (n = 61)
<30 kg Dupilumab 300 mg q4w + TCS (n = 61)
<30 kg Dupilumab 100 mg q2w + TCS (n = 63)
<30 kg Placebo + TCS (n = 60)
<30 kg Dupilumab 300 mg q4w + TCS (n = 61)
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Fig 2. Atopic dermatitis. Proportions of patients with $3- and $4-point improvement in
weekly average of Peak Pruritus NRS over time, in the overall population and the baseline
weight\30 kg and$30 kg subgroups. n, Number of patients with baseline NRS$3 or$4; NRS,
Numerical Rating Scale; q2w, every 2 weeks; q4w, every 4 weeks; TCS, topical corticosteroids.
*P\ .05; ***P\ .0001; all P values in the weight strata are nominal.
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Table III. Safety assessment
Safety assessments































Patients with $1 TEAE, n (%) 88 (73.3) 78 (65.0) 82 (67.2) 43 (71.7) 39 (65.0) 46 (73.0) 45 (75.0) 39 (65.0) 36 (61.0)
Patients with $1 serious TEAE, n (%)* 2 (1.7) 2 (1.7) 0 0 2 (3.3) 0 2 (3.3) 0 0
Patients with $1 TEAE leading to
permanent treatment
discontinuationy
2 (1.7) 0 2 (1.6) 2 (3.3) 0 1 (1.6) 0 0 1 (1.7)
Deaths 0 0 0 0 0 0 0 0 0
TEAEs (PT) reported in $5% of patients,
n (%)
Dermatitis atopic, exacerbation 17 (14.2) 8 (6.7) 10 (8.2) 7 (11.7) 4 (6.7) 8 (12.7) 10 (16.7) 4 (6.7) 2 (3.4)
Asthma 12 (10.0) 2 (1.7) 4 (3.3) 7 (11.7) 0 4 (6.3) 5 (8.3) 2 (3.3) 0
Rhinitis allergic 5 (4.2) 3 (2.5) 4 (3.3) 2 (3.3) 1 (1.7) 3 (4.8) 3 (5.0) 2 (3.3) 1 (1.7)
Nasopharyngitis 8 (6.7) 15 (12.5) 8 (6.6) 2 (3.3) 6 (10.0) 6 (9.5) 6 (10.0) 9 (15.0) 2 (3.4)
Upper respiratory tract infection 12 (10.0) 13 (10.8) 10 (8.2) 5 (8.3) 9 (15.0) 5 (7.9) 7 (11.7) 4 (6.7) 5 (8.5)
Viral upper respiratory tract infection 6 (5.0) 2 (1.7) 1 (0.8) 5 (8.3) 1 (1.7) 1 (1.6) 1 (1.7) 1 (1.7) 0
Vomiting 8 (6.7) 6 (5.0) 6 (4.9) 4 (6.7) 3 (5.0) 2 (3.2) 4 (6.7) 3 (5.0) 4 (6.8)
Cough 9 (7.5) 3 (2.5) 5 (4.1) 5 (8.3) 0 2 (3.2) 4 (6.7) 3 (5.0) 3 (5.1)
Headache 10 (8.3) 6 (5.0) 7 (5.7) 3 (5.0) 1 (1.7) 1 (1.6) 7 (11.7) 5 (8.3) 6 (10.2)
Other adverse events, n (%)
Infections and infestations (SOC) 61 (50.8) 52 (43.3) 49 (40.2) 30 (50) 26 (43.3) 28 (44.4) 31 (51.7) 26 (43.3) 21 (35.6)
Conjunctivitis clusterz 5 (4.2) 8 (6.7) 18 (14.8) 2 (3.3) 4 (6.7) 13 (20.6) 3 (5.0) 4 (6.7) 5 (8.5)
Keratitis clusterx 0 0 1 (0.8) 0 0 1 (1.6) 0 0 0
Skin infection (adjudicated)k 16 (13.3) 7 (5.8) 10 (8.2) 8 (13.3) 4 (6.7) 5 (7.9) 8 (13.3) 3 (5.0) 5 (8.5)
Injection-site reactions (HLT) 7 (5.8) 12 (10.0) 13 (10.7) 4 (6.7) 6 (10.0) 5 (7.9) 3 (5.0) 6 (10.0) 8 (13.6)
Herpes viral infections (HLT) 6 (5.0) 2 (1.7) 4 (3.3) 3 (5.0) 0 3 (4.8) 3 (5.0) 2 (3.3) 1 (1.7)
HLT, MedDRA High Level Term; MedDRA, Medical Dictionary for Regulatory Activities; PT, MedDRA Preferred Term; q2w, every 2 weeks; q4w, every 4 weeks; SOC, MedDRA System Organ Class; TCS,
topical corticosteroids; TEAE, treatment-emergent adverse event.
*Includes 1 event of asthma and 1 event of dermatitis atopic (placebo) and 1 event of food allergy and 1 event of conjunctivitis bacterial (dupilumab 100/200 mg q2w 1 TCS).
yIncludes 1 event of asthma and 1 event of dermatitis atopic (placebo) and 1 event of food allergy and 1 event of urinary tract infection (dupilumab 300 mg q4w 1 TCS). Adverse events were
reported according to MedDRA PTs unless otherwise specified.
zConjunctivitis cluster includes the PTs conjunctivitis, conjunctivitis allergic, conjunctivitis bacterial, conjunctivitis viral, and atopic keratoconjunctivitis.
xKeratitis cluster includes the PTs keratitis, ulcerative keratitis, allergic keratitis, atopic keratoconjunctivitis, and ophthalmic herpes simplex.










































dupilumab 1 TCS than with placebo 1 TCS, which
might be related to the effect of dupilumab on
comorbid type 2 inflammatory conditions and on
skin infections.22 Of importance, this pediatric study
population with severe AD has a high burden of
comorbid type 2 or allergic conditions: almost half of
these children have asthma, about 60% have allergic
rhinitis, and about 65% report food allergies. In
addition, children with severe AD are at markedly
increased risk of skin infections.24
Consistent with the concept that patients with
severe AD have a systemic perturbation in their
immune axisdresulting from Th-2 polarizationdthat
can be addressed with dupilumab,25,26 dupilumab
1 TCS not only improved all measures of AD in these
patients, but resulted in a decrease in type 2 AEs. In
addition, because infections in patients with AD result
from a breakdown in skin integrity, and because
dupilumab treatment can restore skin integrity,27 as
expected, dupilumab 1 TCS was associated with
lower rates of skin and herpes virus infections.22
Dupilumab 1 TCS-associated decreases in type 2
comorbidities and infections were correlated with
pharmacokinetic exposure. The benefit of dupilumab
in regard to infections runs counter to experiencewith
immunomodulatory therapiesdsuch as corticoste-
roids, cyclosporine, Janus kinase inhibitors, tumor
necrosis factor inhibitors, azathioprine, and FK506
inhibitorsdthat tend to be profoundly immunosup-
pressive. There is an obvious benefit in this pediatric
population for AD treatment that can also address
associated comorbid atopic conditionswhile avoiding
immunosuppression.
As observed previously in adults and adolescents
with AD,18,28 conjunctivitis incidence in this trial was
higher in patients treated with dupilumab 1 TCS.
The highest incidence of conjunctivitis (24%)
occurred in the treatment group with the lowest
exposure (100 mg q2w 1 TCS), which is consistent
with previous analyses suggesting that conjunctivitis
associated with dupilumab results from relative
undertreatment within the eye compartment.28
Study strengths are the randomized, prospective,
double-blinded, placebo-controlled design and the
use of validated assessments. Limitations include the
relatively short 16-week treatment period and the
restriction, per agreement with regulatory author-
ities, to children with severe disease. A pediatric
open-label extension study is ongoing.
This study, the first, to our knowledge, of a
targeted biologic agent in children aged 6-11 years
with severe AD, demonstrated clear efficacy of
dupilumab 1 TCS in all disease measures, including
extent and severity of signs, intensity of symptoms,
sleep, and QOL. The safety profile was consistent
with that observed in adults and adolescents. Both
the 300 mg q4w 1 TCS and the 100/200 mg
q2w 1 TCS regimens of dupilumab provided sub-
stantial clinical benefit for signs and symptoms of
AD.
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Pharmaceuticals, Inc), and Nicolas Duverger, El-Bdaoui
Haddad, Elizabeth Laws, Leda Mannent, and Christine Xu
(Sanofi) for their contributions.
REFERENCES
1. Mortz CG, Andersen KE, Dellgren C, et al. Atopic dermatitis
from adolescence to adulthood in the TOACS cohort:
prevalence, persistence and comorbidities. Allergy. 2015;70:
836-845.
2. Hay RJ, Johns NE, Williams HC, et al. The global burden of skin
disease in 2010: an analysis of the prevalence and impact of
skin conditions. J Invest Dermatol. 2014;134:1527-1534.
3. Beattie PE, Lewis-Jones MS. A comparative study of impair-
ment of quality of life in children with skin disease and
children with other chronic childhood diseases. Br J Dermatol.
2006;155:145-151.
4. Chamlin SL. The psychosocial burden of childhood atopic
dermatitis. Dermatol Ther. 2006;19:104-107.
5. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care
for the management of atopic dermatitis: section 1. Diagnosis
and assessment of atopic dermatitis. J Am Acad Dermatol.
2014;70:338-351.
6. Huang E, Ong PY. Severe atopic dermatitis in children. Curr
Allergy Asthma Rep. 2018;18:35.
7. Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema
prevalence in the United States: data from the 2003 National
Survey of Children’s Health. J Invest Dermatol. 2011;131:67-
73.
8. Wollenberg A, Ehmann LM. Long term treatment concepts
and proactive therapy for atopic eczema. Ann Dermatol. 2012;
24:253-260.
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